Biosion

📍 Nanjing, China🗓 Founded 2017👥 23 employees💰 Last funded Feb 2023
Biotechnology Research🌐 biosion.com
Website LinkedIn
Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China. To learn more about Biosion visit www.biosion.com.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Biosion?
Biosion has 1 investors on record on gritt.io and 1 late-stage investors.
When did Biosion last raise funding?
The most recent investment in Biosion recorded on gritt.io was in February 2023.
When was Biosion founded?
Biosion was founded in 2017.
What industry is Biosion in?
Biosion operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Biosion based?
Biosion is headquartered in Nanjing, China.